Key Metrics of Allchem Lifescience Limited
About Allchem Lifescience Limited
Sectors
Company details
- Registered office
- Village Manjusar, Savli, Vadodara, In-gj, 391775
Operational Areas of Allchem Lifescience Limited
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 10 Jun 2026 | ICRA | Reaffirmed | BBB- | A3 | Stable | ₹155 Cr | View |
| 26 Sep 2025 | CARE | Downgraded | B+ | — | Stable | ₹24.8 Cr | View |
| 23 Sep 2024 | CARE | Non-cooperating | BB- | A4 | Stable | ₹24.8 Cr | View |
| 20 Jul 2023 | CARE | Non-cooperating | BB- | A4 | Stable | ₹24.8 Cr | View |
| 23 Jun 2022 | CARE | Non-cooperating | BB- | A4 | Stable | ₹24.8 Cr | View |
| 14 Apr 2021 | CARE | Non-cooperating (from BB) | BB- | A4 | Stable | ₹49.6 Cr | View |
| 01 Apr 2020 | CARE | Non-cooperating | BB | A4 | Stable | ₹49.6 Cr | View |
| 20 Feb 2019 | CARE | Assigned | BB | A4 | Stable | ₹24.8 Cr | View |
Credit strengths (ICRA, Jun 2026)
+ Strong promoter background and established track record of Allchem in manufacturing drug intermediates
Mr. Bipin Patel is the founder and promoter of the company and has over two decades of experience in the pharmaceutical industry.
+ Strong relationships with customers ensure repeat orders; diversified product portfolio
The company's proven capabilities have enabled it to secure orders from reputed clients.
+ Technical competence to develop new chemical intermediates and update product offerings
Since its incorporation as a proprietorship firm in 2003, the company spent almost a decade on research and development(R&D), enabling it to develop more than 250 intermediates, before commencing commercial production from 2013.
+ Despite contraction in FY2026, operating margins remain healthy
Despite an 11% decline in revenues in FY2026, the company was able to sustain operating margins above 33%.
Credit challenges
− Moderate scale of operations, restricting operational flexibility to some extent
The company’s scale of operations remains moderate, restricting its operational flexibility and the benefits from the economies of scale to a certain extent.
− Operates in highly competitive and regulated industry
The company operates amid intense competition, exposing it to pricing pressure.
− Modest debt coverage metrics and high working capital intensity
The total project cost for the capacity expansion undertaken by the company (for which FY2025 was the first full fiscal of production) was Rs. 128.8 crore, which was funded through a combination of internal accruals and term loan from banks.
− Susceptible to fluctuations in raw material prices, foreign exchange rates
The company’s profitability remains exposed to adverse volatility in raw material prices.
Could lead to an upgrade
ICRA could upgrade the company’s ratings, in case of any significant increase in the scale of operations (by improving its capacity utilisation) and net worth with improvement in its
Could lead to a downgrade
Pressure on the ratings could arise if there is any material deterioration in its revenues and earnings on account of continued pricing pressure leading to moderation in debt metrics and
Agency-reported financials (ICRA, 10 Jun 2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Operating income | ₹138 Cr | ₹153 Cr | ₹136 Cr |
| PAT | ₹23.40 Cr | ₹24.10 Cr | ₹7.60 Cr |
| OPBDIT/OI | 38.3% | 43.6% | 33.4% |
| PAT/OI | 17.0% | 15.8% | 5.6% |
| Total outside liabilities/Tangible net worth (times) | 1.80× | 1.60× | 1.60× |
| Total debt/OPBDIT (times) | 2.00× | 2.00× | 3.10× |
| Interest coverage (times) | 8.30× | 6.30× | 3.70× |
| Revenue growth (YoY) | — | 10.6% | −11.1% |
| EBITDA (margin × income) | ₹52.85 Cr | ₹66.53 Cr | ₹45.32 Cr |
| Implied total debt (debt/EBITDA × EBITDA) | ₹106 Cr | ₹133 Cr | ₹140 Cr |
| Implied interest cost (EBITDA ÷ coverage) | ₹6.37 Cr | ₹10.56 Cr | ₹12.25 Cr |
Borrowings & rated debt
Rated limits over time
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Long-term Fund-based – Term to Loan Long-term Short-term – Fund | Working capital & bank lines | ₹74.6 Cr | ₹101 Cr | 34.9% | BBB- (Stable) | Reaffirmed | ICRA |
| based Non-fund based | Non-fund based limits | ₹40.5 Cr | ₹40.5 Cr | 0.0% | BBB- / A3 (Stable) | Reaffirmed | ICRA |
| to Working Capital Long-term Short-term – to Unallocated | Working capital & bank lines | ₹1.90 Cr | ₹13.8 Cr | 623.7% | BBB- / A3 (Stable) | Reaffirmed | ICRA |
CARE ratings on record (checked 30 Oct 2026)
| Instrument | Amount | Rating |
|---|---|---|
| Cash Credit | ₹13.5 Cr | CARE B+; Stable / CARE A4; ISSUER NOT COOPERATING* |
| Term Loan | ₹11.3 Cr | CARE B+; Stable; ISSUER NOT COOPERATING* |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 52% |
| Information on file | 67% · missing: Capex / investment plans, Auditor details, Shareholding pattern |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 50% chance the next rating action is stable or better
- Current rating BBB- (investment grade)
- Interest coverage 3.7×
- Working-capital limits 72% utilised on average
- ₹13.75 cr of rated limits not yet tied to a lender
Rated limits by facility
Timeline
From the report
June 10, 2026 Allchem Lifescience Limited: Ratings reaffirmed; outlook revised to stable from positive; rated amount enhanced Summary of rating action Previous rated amount Current rated amount Instrument* Rating action (Rs. crore) (Rs. crore) [ICRA]BBB- (Stable); reaffirmed; outlook Long-term Fund-based – Term 74.60 100.66 revised to Stable from Positive; assigned Loan for enhanced amount Long-term/ Short-term – Fund- [ICRA]BBB- (Stable)/ [ICRA]A3; reaffirmed; based/ Non-fund based – 40.50 40.50 outlook revised to Stable from Positive Working Capital [ICRA]BBB- (Stable)/ [ICRA]A3; reaffirmed;
From the report
Unallocated assigned for enhanced amount Total 117.00 154.91 *Instrument details are provided in Annexure II Rationale The revision in the rating outlook of Allchem Lifescience Limited (Allchem/the company) reflects its weaker-than-expected performance in FY2026 when its revenues declined and its margins contracted sharply, following significant pricing pressures that impacted its realisations, despite the production volumes being largely in line with the previous fiscal.
From the report
The company availed incremental term debt for its capacity expansion and the solar power project in FY2025 and FY2026, respectively, which resulted in a steady increase in its debt levels.
From the report
The company has also availed term debt for setting up its power plant, which was completed in FY2026.
From the report
Liquidity position: Adequate Allchem’s liquidity position remains adequate, supported by an available working capital buffer of Rs. 26.6 crore against sanctioned limits of Rs. 40.5 crore as on March 31, 2026.
From the report
The company’s average working capital utilisation stood at around 72% of the sanctioned limit of Rs. 40.5 crore during April 2025–March 2026.
From the report
The company’s average working capital utilisation stood at around 72% of the sanctioned limit of Rs. 40.5 crore during April 2025–March 2026.
From the report
The company has scheduled repayment obligations of Rs. 17.6 crore in FY2027 and Rs. 18.0 crore in FY2028 towards its existing debt.
From the report
The cash flow from operating activity was at negative Rs.2.58 crore during FY18 and cash on hand stood low at Rs.0.15 crore as on March 31, 2018.
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Allchem Lifescience Limited
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Dr. Reddy's Laboratories |
Part of Dr. Reddy's Laboratories. | drreddys.com | 1984 | India |
 Aurobindo Pharma |
Part of Aurobindo Pharma. | aurobindo.com | 1986 | Hyderabad, India |
 Cipla |
Part of Cipla. | cipla.com | 1935 | Mumbai, India |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lupin.com | 1968 | India | |
 Glenmark Pharmaceuticals |
Part of Glenmark Pharmaceuticals. | glenmarkpharma.com | 1977 | Mumbai, India |
| Part of Biocon. | biocon.com | 1978 | Bangalore, India | |
 Alkem Laboratories Limited |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | alkemlabs.com | 1973 | Mumbai, Maharashtra, India |
 Torrent Pharmaceuticals |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | torrentpharma.com | 1959 | Ahmedabad, India |
| Aster DM Quality Care Limited | Discovered Companies · Other Industries | — | — | Hyderabad, Telangana, India |
 Thomas Cook India |
Part of Thomas Cook Group. | thomascook.in | 1978 | Mumbai, India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.